SCHEMBL12128397

SCHEMBL12128397

Cn1cc(C2CCCCC2)c2ccc(Nc3ccc(F)c(F)c3)nc21

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
APP P05067 5/20 0.53
DHFR P00374 2/20 0.38
SCN9A Q15858 3/20 0.37
SCN5A Q14524 1/20 0.35
CSNK2A2 P19784 1/20 0.35
CAMK1D Q8IU85 1/20 0.35
MAPT P10636 2/20 0.34
KDM4E B2RXH2 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
TP53 P04637 1/20 0.34
HTR6 P50406 1/20 0.34
CCR4 P51679 1/20 0.34
CDK2 P24941 1/20 0.33
MAPKAPK2 P49137 1/20 0.33
RORC P51449 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12129676 0.90 APP (0.55) APPDHFRHTR6
SCHEMBL12129153 0.89 APP (0.69) APPDHFRHTR6MAPKAPK2
SCHEMBL12128394 0.85 APP (0.46) APPDHFRCSNK2A2CAMK1DMAPT
SCHEMBL12128461 0.82 CHEK1 (0.42) APPMAPTKDM4ENPC1RAB9A
SCHEMBL12128666 0.82 ABCB1 (0.41) MAPTKDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL12285337 0.81 SCN9A (0.47) APPSCN9AMAPTTP53
SCHEMBL12128678 0.81 SYK (0.41) APPCSNK2A2CDK2
SCHEMBL12128672 0.80 APP (0.40) APPSCN9ASCN5ARORC
SCHEMBL12128025 0.80 EHMT2 (0.47) APPHTR6
SCHEMBL12129632 0.79 APP (0.55) APPCDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160158242-A1 Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins AC IMMUNE SA (CH) 2016-06-09 US disclosed
US-9221812-B2 Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins AC IMMUNE SA (CH) 2015-12-29 US disclosed
US-20110280808-A1 Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins AC IMMUNE, S.A. (CH) 2011-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110280808-A1 Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins APP, PSEN1, PSEN2 APP 1/4885DHFR 4024/4885SCN9A 3449/4885
US-20160158242-A1 Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins APP, PSEN1, PSEN2 APP 1/4885DHFR 4024/4885SCN9A 3449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.